Inclusion Criteria:  Physician-diagnosed COPD Having been prescribed treatment with TRIXEO according to label and local market reimbursement criteria Patients must be able and willing to read and to comprehend written instructions, and to comprehend and complete the questionnaires required by the protocol After full explanation, patients must have signed an informed consent document indicating that they understand the purpose of and the procedures required for the study and are willing to participate in the study.  Exclusion Criteria:  COPD due to α-1 antitrypsin deficiency Previous treatment with any other triple fixed-dose combination during screening Hospitalisation due to COPD exacerbation within the last 4 weeks prior to enrolment Pregnancy or lactation period Participation in an observational trial that might, in the investigator's opinion, influence the assessment for the current study, or participation in a randomised clinical trial in the last 30 days. Patient still recovering from Covid-19 infection